HSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $157 from $150 and keeps a Reduce rating on the shares. In a sector...
Source LinkHSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $157 from $150 and keeps a Reduce rating on the shares. In a sector...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.